Cargando…

Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation

The feasibility of de novo everolimus without calcineurin inhibitor (CNI) therapy following liver transplantation was assessed in a multicenter, prospective, open-label trial. Liver transplant patients were randomized at 4 weeks to start everolimus and discontinue CNI, or continue their current CNI-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sterneck, M, Kaiser, G M, Heyne, N, Richter, N, Rauchfuss, F, Pascher, A, Schemmer, P, Fischer, L, Klein, C G, Nadalin, S, Lehner, F, Settmacher, U, Neuhaus, P, Gotthardt, D, Loss, M, Ladenburger, S, Paulus, E M, Mertens, M, Schlitt, H J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285226/ https://www.ncbi.nlm.nih.gov/pubmed/24502384 http://dx.doi.org/10.1111/ajt.12615

Ejemplares similares

Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial
por: Nashan, Björn, et al.
Publicado: (2021)

Living donor liver transplantation with two-stage hepatectomy for patients with isolated, irresectable colorectal liver—the LIVER-T(W)O-HEAL study
por: Rauchfuß, Falk, et al.
Publicado: (2019)

The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial
por: Van Keer, Jan, et al.
Publicado: (2017)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial
por: Nashan, Bjorn, et al.
Publicado: (2015)

Preclinical evidence to support repurposing everolimus for craving reduction during protracted drug withdrawal
por: Chiu, Alvin S., et al.
Publicado: (2021)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
por: Bergh, Niklas, et al.
Publicado: (2020)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients
por: Pacheco, Larissa Sgaria, et al.
Publicado: (2018)

The Privilege of Induction Avoidance and Calcineurin Inhibitors Withdrawal in 2 Haplotype HLA Matched White Kidney Transplantation
por: Brifkani, Zaid, et al.
Publicado: (2017)

A systematic review and meta-analysis comparing everolimus and calcineurin inhibitors (CNIs) to mycophenolate and CNIs in kidney transplant patients
por: Vergara-Rejante, Larraine, et al.
Publicado: (2023)

Posttraumatic venous gas in the liver – a case report and review of the current literature
por: Fahrner, René, et al.
Publicado: (2018)

Ligation of the middle hepatic vein to increase hypertrophy induction during the ALPPS procedure
por: Dondorf, F., et al.
Publicado: (2021)

Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study
por: Saliba, Faouzi, et al.
Publicado: (2022)

Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an ex vivo tacrolimus perfusion
por: Pratschke, Sebastian, et al.
Publicado: (2013)

Epidemiological Pattern of Hepatitis B and Hepatitis C as Etiological Agents for Hepatocellular Carcinoma in Iran and Worldwide
por: Zidan, Ahmed, et al.
Publicado: (2012)

Calcineurin
por: Creamer, Trevor P.
Publicado: (2020)

Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001)
por: Schmelzle, Moritz, et al.
Publicado: (2022)

Calcineurin Inhibitors and COVID-19
por: Hage, René, et al.
Publicado: (2022)

Calcineurin Inhibitors and COVID-19
por: Hage, René, et al.
Publicado: (2022)

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis
por: Rafael-Vidal, Carlos, et al.
Publicado: (2021)

Calcineurin Governs Thermotolerance and Virulence of Cryptococcus gattii
por: Chen, Ying-Lien, et al.
Publicado: (2013)

Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study
por: Watarai, Yoshihiko, et al.
Publicado: (2021)

Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study
por: Eisenberger, Ute, et al.
Publicado: (2018)

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial
por: Hoffmann, Katrin, et al.
Publicado: (2015)

Gas Chromatography–Mass Spectrometry Detection of Thymoquinone in Oil and Serum for Clinical Pharmacokinetic Studies
por: Tekbaş, A., et al.
Publicado: (2023)

Innovationen in der Leberchirurgie durch die Transplantation mit Lebendspende
por: Settmacher, U., et al.
Publicado: (2003)

The PRAISE study: A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of iloprost in the early postoperative period after liver transplantation (ISRCTN12622749)
por: Bärthel, Erik, et al.
Publicado: (2013)

Accept or refuse? Factors influencing the decision-making of transplant surgeons who are offered a pancreas: results of a qualitative study
por: Loss, Julika, et al.
Publicado: (2013)

Calcineurin and glial signaling: neuroinflammation and beyond
por: Furman, Jennifer L, et al.
Publicado: (2014)

Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis
por: Yamanaka, Kenya, et al.
Publicado: (2013)

Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma
por: Rauchfuß, Falk, et al.
Publicado: (2022)

Postoperative Outcomes in 415 Patients Following Liver Transplantation Using Extended Donor Criteria: A Study from a Single Center in Germany
por: Deeb, Aladdin Ali, et al.
Publicado: (2023)

Adipose tissue induces a better liver regeneration after living liver donation in normal weight donors
por: Deeb, Aladdin Ali, et al.
Publicado: (2023)

Value of palliative surgery in perihilar cholangiocarcinoma
por: Dondorf, Felix, et al.
Publicado: (2023)

Liver Transplantation for Incidental Cholangiocarcinoma or Combined Hepatocellular Carcinoma/Cholangiocarcinoma—Own Experiences and Review of the Literature
por: Schwenk, Laura, et al.
Publicado: (2023)

BUPRENORPHINE WITHDRAWAL SYNDROME
por: Tripathi, B.M., et al.
Publicado: (1995)

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
por: Rugo, H. S., et al.
Publicado: (2016)

Long-Term Habituation of the Gill-Withdrawal Reflex in Aplysia Requires Gene Transcription, Calcineurin and L-Type Voltage-Gated Calcium Channels
por: Esdin, Joseph, et al.
Publicado: (2010)

Characterization of calcineurin from Cryptococcus humicola and the application of calcineurin in aluminum tolerance
por: Zhang, Lei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_keju0ie0i1c7h5al84np6p6lep